Compare · SRDX vs SYK
SRDX vs SYK
Side-by-side comparison of Surmodics Inc. (SRDX) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SRDX and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $117.18B, about 195.8x SRDX ($598.4M).
- Over the past year, SRDX is up 47.8% and SYK is down 20.7% - SRDX leads by 68.5 points.
- SYK has hit the wire 8 times in the past 4 weeks while SRDX has been quiet.
- SYK has more recent analyst coverage (25 ratings vs 7 for SRDX).
- Company
- Surmodics Inc.
- Stryker Corporation
- Price
- $42.99+0.33%
- $303.19-0.80%
- Market cap
- $598.4M
- $117.18B
- 1M return
- +52.83%
- +3.01%
- 1Y return
- +47.83%
- -20.66%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 1998
- News (4w)
- 0
- 8
- Recent ratings
- 7
- 25
Surmodics Inc.
Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. The company operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The Vitro Diagnostics segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. Surmodics, Inc. was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest SRDX
- SEC Form 15-12G filed by Surmodics Inc.
- SEC Form EFFECT filed by Surmodics Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Surmodics Inc.
- SVP, Medical Device Coatings Olson Charles W returned 52,278 shares to the company, closing all direct ownership in the company (SEC Form 4)
- VP Finance, Corp. Controller Manders John D. returned 8,155 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Sr. VP of Legal, GC and Sec. Weber Gordon S. returned 21,040 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SVP, Vascular Interventions Sides Teri Woodwick returned 34,703 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Dantzker David returned 40,183 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Heine Lisa Wipperman returned 13,978 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Knight Susan E returned 37,240 shares to the company, closing all direct ownership in the company (SEC Form 4)
Latest SYK
- President and COO Stiles Spencer S gifted 1,607 shares, decreasing direct ownership by 2% to 76,027 units (SEC Form 4)
- Stryker launches TPX HD® power tool, supporting demanding orthopaedic procedures
- VP, Chief Legal Officer Fletcher Robert S sold $1,394,409 worth of shares (4,544 units at $306.87) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 10,582 units (SEC Form 4)
- Director Stryker Ronda E sold $96,792,669 worth of shares (310,000 units at $312.23) (SEC Form 4)
- Stryker Launches Pangea Plating System and Completes First Case in Europe
- SEC Form SD filed by Stryker Corporation
- SEC Form 8-K filed by Stryker Corporation
- BioStar Capital-Backed Amplitude Vascular Systems' $835M Acquisition by Stryker Reflects Strength of Michigan's Medtech Ecosystem
- VP, Chief HR Officer Fink M Kathryn exercised 21,582 shares at a strike of $167.98, covered exercise/tax liability with 16,362 shares and sold $2,473,756 worth of shares (8,720 units at $283.69) (SEC Form 4)
- SEC Form 10-Q filed by Stryker Corporation